This functionality is implemented using Javascript. It cannot work without it, etc...

We are loading the information...

Skip to main content

Medical Policies

Medical policies are documents that define the plan coverage for technologies, procedures and treatments. The statements of medical necessity in the policies, about whether a technology, procedure, treatment, supply, equipment, drug or other service improves the health outcome of the population for which said technology or treatment was designed are based on scientific evidence, clinical studies and professional opinions from our providers and recognized medical organizations.

Each document displayed on this website is provided for informational purposes only and is not an authorization, explanation of benefits, or contract. Receiving benefits is subject to satisfaction of all terms and conditions of coverage. Medical technology is constantly changing, and we reserve the right to periodically review and update our policies.

ID Title Last Review Next Review Description Access
P1.002.013 Adstiladrin® (nadofaragene firadenovec-vncg) Feb 20, 2025 Feb 20, 2026 Adstiladrin is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult... View
P1.002.014 AMTAGVI (Lifileucel) Sep 22, 2025 Sep 20, 2026 Amtagvi (lifileucel) is an autologous til (tumor-infiltrating lymphocyte) therapy approved by the fda in... View
P1.002.015 AUCATZYL (Obecabtagene autoleucel) Sep 22, 2025 Sep 20, 2026 Aucatzyl is an autologous anti-cd19 car-t therapy indicated for adults with relapsed or refractory b-cell... View
P1.002.016 ENCELTO (Revakinagene taroretcel-lwey) Sep 22, 2025 Sep 20, 2026 Encelto (revakinagene taroretcel-lwey) is a cell-based implant designed to continuously deliver recombinant... View
P1.002.017 KEBILIDI (Eladocagene exuparvovec-tneq) Sep 22, 2025 Sep 20, 2025 Kebilidi is an adeno-associated virus (aav) vector-based gene therapy 12 indicated for the treatment of adult... View
P1.002.018 LANTIDRA (Donislecel) Sep 22, 2025 Sep 20, 2026 Lantidra (donislecel-jujn) is an allogeneic pancreatic islet cell therapy approved by the fda in june 2023.... View
P1.002.019 LAVIV  (Azficel-T) Sep 02, 2025 Sep 20, 2026 Azficel-t is an autologous cellular product composed of fibroblasts indicated for improvement of the... View
P1.002.021 OMISIRGE (Omidubicel-onlv) Sep 22, 2025 Sep 20, 2026 ... View
P1.002.022 RETHYMIC (Allogeneic processed thymus tissue – agdc) Sep 22, 2025 Sep 20, 2026 Allogeneic processed thymus tissue–agdc (rethymic) was approved by the us food and drug administration... View
P1.002.023 RYONCIL (Remestemcel-L-rknd) Sep 22, 2025 Sep 20, 2026 Remestemcel-l-rknd (ryoncil) is fda-approved for the treatment of steroid-refractory acute graftversus-host... View
P1.002.024 SKYSONA (Elivaldogene autotemcel) Sep 22, 2025 Sep 20, 2026 Cerebral adrenoleukodystrophy (cald) is an x-linked genetic neurodegenerative disease that most severely... View
P1.002.026 TECELRA  (Afamitresgene autoleucel) Sep 22, 2025 Sep 26, 2026 Tecelra (afamitresgene autoleucel) is a melanoma-associated antigen a4 (magea4)-directed genetically modified... View
P1.002.028 AXTLE (pemetrxed) Sep 22, 2025 Sep 20, 2026 Pemetrexed (alimta) was initially approved by the u.s. food and drug administration (fda) in february 2004... View
P1.002.033 Gefitinib Sep 22, 2025 Sep 20, 2026 Gefitinib (iressa®) is an orally administered tyrosine kinase inhibitor (tki) of the epidermal growth... View
PP.001.001 Dose Rounding of Drug Covered Under The Medical Benefit May 14, 2025 May 20, 2026 ... View
PP.001.002 Leuprolide May 14, 2025 May 20, 2026 (leuprolide acetate) – a drug that is a manufactured version of a hormone. it is a hormone-releasing... View
PP.002.002 Discontinued Procedures/Reduced Services – Modifiers 73 & 74 Aug 11, 2025 Aug 20, 2026 The term "discontinued procedure" designates a surgical or diagnostic procedure provided by a... View
PP.002.004 Split Surgical Package Jun 21, 2024 Jun 20, 2025 ... View
787-277-6653 787-474-6326